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ABSTRACT
We show that suppression of the spliceosome has potential for the treatment 
of cutaneous squamous cell carcinoma (cSCC). The small-molecule inhibitors of the 
spliceosome at the most advanced stage of development target the splicing factor 
SF3B1/SF3b155. The majority of cSCC cell lines are more sensitive than normal skin 
cells to death induced by the SF3B1 inhibitor pladienolide B. Knockdown of SF3B1 
and a range of other splicing factors with diverse roles in the spliceosome can also 
selectively kill cSCC cells. We demonstrate that endogenous c-MYC participates in 
conferring sensitivity to spliceosome inhibition. c-MYC expression is elevated in cSCC 
lines and its knockdown reduces alterations in mRNA splicing and attenuates cell death 
caused by interference with the spliceosome. In addition, this study provides further 
support for a key role of the p53 pathway in the response to spliceosome disruption. 
SF3B1 inhibition causes wild-type p53 upregulation associated with altered mRNA 
splicing and reduced protein expression of both principal p53 negative regulators 
MDMX/MDM4 and MDM2. We observed that wild-type p53 can promote pladienolide 
B-induced death in tumour cells. However, p53 is commonly inactivated by mutation 
in cSCCs and p53 participates in killing normal skin cells at high concentrations of 
pladienolide B. This may limit the therapeutic window of SF3B1 inhibitors for cSCC. 
We provide evidence that, while suppression of SF3B1 has promise for treating cSCCs 
with mutant p53, inhibitors which target the spliceosome through SF3B1-independent 
mechanisms could have greater cSCC selectivity as a consequence of reduced p53 
upregulation in normal cells. 
INTRODUCTION
cSCC is responsible for a substantial proportion of 
deaths from skin cancer and can also have a considerable 
impact on the quality of life [1–5]. Immunosuppressed 
patients, including organ transplant recipients, have an 
increased incidence of aggressive cSCCs [2]. In patients 
with the genetic skin blistering disease severe generalized 
recessive dystrophic epidermolysis bullosa (RDEB) the 
cumulative mortality risk from cSCC is 80% by the age of 
55 [4]. There is a need for improvements in the treatment 
of cSCC both in the general population and in high-risk 
groups [1–7]. Effective systemically-delivered therapy 
is required for cSCC patients with distant metastasis. In 
addition, some cSCC patients with localised disease would 
benefit from improved directly-delivered therapy (topical 
treatment or intratumoral injection) [1, 7–9]. 
Our siRNA screen identified the spliceosome as 
a potential target for cSCC therapy. The spliceosome 
generates mature mRNA by the splicing of pre-mRNA 
which involves the removal of introns and the joining of 
exons. This is essential for gene expression. In addition, 
alternative splicing makes a major contribution to genetic 
diversity. The spliceosome contains over one hundred and 
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fifty different proteins (splicing factors) and its structure 
and composition are highly dynamic [10, 11]. Core 
components of the spliceosome are the U1, U2, U4, U5 
and U6 small nuclear ribonucleoprotein (snRNP) particles 
[12–14]. Each snRNP contains a small nuclear RNA 
(snRNA) and the spliceosome is thought to be a ribozyme 
where the snRNA play a catalytic role that is directed 
by associated proteins [11, 15]. In vitro studies show 
that the U1 snRNP interacts with the 5′ splice site and 
the U2 snRNP associates with the intronic branch-point. 
This is followed by the recruitment of the U4/U6.U5 tri-
snRNP. The U1 and U4 snRNPs are destabilised and the 
spliceosome catalyses two transesterification reactions. A 
bond is formed between the 5′ splice site and an adenosine 
in the branch-point causing cutting of the intron and this is 
followed by ligation of 5′ and 3′ splice sites. 
There is growing interest in targeting the 
spliceosome for cancer therapy [16–18]. The spliceosome 
may appear to be a surprising therapeutic target because 
of its importance in normal cells. However, cancers can be 
more susceptible than untransformed cells to spliceosome 
inhibition [19–21]. Importantly, only a subset of splicing 
events is affected by knockdown of a particular core 
splicing factor: there are alterations in splice site selection 
rather than generalised inhibition of splicing and the 
effects of suppressing different core splicing factors can 
be divergent [22]. In support of the ability of patients to 
tolerate spliceosome inhibition many therapies which 
are commonly used to treat cancer have affects on the 
spliceosome and pre-RNA splicing, including DNA 
damaging agents and 5-fluorouracil [23–25]. For example, 
5-fluorouracil is incorporated into the U2 snRNA which 
interferes with splicing [23]. 
The most advanced small-molecule spliceosome 
inhibitors target the SF3B complex which is a multisubunit 
component of the U2 snRNP. SF3B binds to pre-mRNA in 
the vicinity of the branch-site and consequently participates 
in splice site recognition and selection [26]. Several families 
of naturally occurring compounds with anti-tumour activity 
have been found to target the spliceosome through an 
interaction with this complex [16, 18]. Synthetic analogues 
of these inhibitors have now been generated [21, 27, 28]. 
The splicing factor SF3B1 is one of seven subunits of the 
SF3B complex and it is thought to be a direct target for these 
compounds [29–31]. Pladienolide B is is an example of a 
naturally occurring spliceosome inhibitor that interacts with 
SF3B1 [32, 33]. A point mutation in SF3B1 has been shown 
to decrease the binding of pladienolide B to the spliceosome 
and to dramatically reduce the potency of its effects on cell 
viability [29]. SF3B1 inhibitors have good pre-clinical 
anti-tumour activity in model systems [17, 21, 32, 34, 35]. 
Systemically delivered E7107 was the first SF3B inhibitor 
to be tested in clinical trials but there were adverse effects 
in a small number of patients [36, 37]. The SF3B inhibitor 
H3B-8800 has recently entered a phase 1 clinical trial 
involving oral delivery for patients with haematological 
malignancies (NCT02841540). Additional small molecule 
modulators of the SF3B complex are candidates for testing 
in clinical trials [28]. 
A number of pathways can influence the sensitivity 
of cell viability to interference with the spliceosome. 
Ectopic expression of the transcription factor c-MYC 
sensitises normal cells including neural stem cells, 
fibroblasts and mammary epithelial cells, to modulation 
of the spliceosome [19, 38]. It has been proposed that 
c-MYC upregulation places a burden on the spliceosome 
by causing a widespread increase in transcription [19]. 
Synthetic lethality with spliceosome inhibition could 
provide a means to treat the many tumours with elevated 
c-MYC [39, 40]. This is of great interest because c-MYC 
is difficult to target directly [41, 42]. Altered splicing of 
the mRNAs coding for the anti-apoptotic proteins BCL-X 
and MCL-1 can also contribute to the anti-tumour activity 
of targeting the spliceosome [43–48]. In addition, we have 
shown previously that interference with the spliceosome 
by multiple mechanisms results in wild-type p53 
activation [49]. Consistent with this three splicing factors 
were top ten hits, ranked according to the magnitude of 
p53 transcriptional activation, in a recent genome wide 
siRNA screen in non-small cell lung cancer cells [50]. 
In unstressed cells p53 is held in check by MDMX and 
MDM2 [51, 52]. They both inhibit the transcriptional 
activity of p53. MDM2 is an E3 ligase which promotes 
p53 ubiquitination leading to degradation of p53 by the 
proteasome. MDMX can stimulate the ubiquitin ligase 
activity of MDM2 by forming an MDMX/MDM2 
heterodimer. We reported that a reduction in the level of 
MDMX acts as a sensor of alterations in the spliceosome 
independently of DNA-damage signalling [49]. Similar 
observations have now been made in other in vitro and 
in vivo systems [50, 53, 54]. This can involve changes in 
MDMX mRNA splicing due to weak splice sites that are 
sensitive to interference with the spliceosome but other 
mechanisms may also contribute, including enhanced 
MDMX protein degradation [49, 50, 53, 54]. 
In this study we observed that suppression of the 
spliceosome by targeting a range of splicing factors can 
selectively kill cSCC cells compared to normal skin cells. 
We sought to identify mechanisms that influence this 
tumour selectivity. Our results indicate that endogenous 
c-MYC upregulation contributes to sensitising cSCC cells 
to inhibition of the spliceosome. In addition, we show that 
wild-type p53 can play a dominant role in promoting cell 
death caused by small molecule SF3B1 inhibition in both 
tumour cells and in normal skin cells. Consistent with 
previous observations, suppression of SF3B1 reduces 
the expression of MDM2 as well as MDMX and causes 
strong upregulation of wild-type p53 [49, 55]. We show 
that small molecule inhibition of the splicing factor 
SF3B1 has promise for treating cSCCs with mutant p53. 
However, this study suggests that by avoiding robust 
p53 upregulation in normal cells SF3B1-independent 
Oncotarget23031www.oncotarget.com
suppression of the spliceosome could further extend the 
therapeutic window for cSCCs in which normal p53 
function is lost. 
RESULTS
Targeting the spliceosome can selectively kill 
cSCC cells
To identify potential targets for cSCC therapy an 
siRNA screen was carried out in SCCRDEB4 cells with 
reduced cell viability as a readout (data not shown). Based 
on Cvitkovic et al., [10] the library used for the screen 
contained siRNAs targeting ten splicing factors [56, 57]. 
Six of these splicing factors: SF3B3/SF3b130, PHF5A/
SF3b14b, PRPF8/PRP8, UBL5/HUB1, USP39 and 
PRPF19 were among the top hits. SF3B3 and PHF5A are 
components of the SF3B complex [26]. PRPF8 occupies 
a core position in the spliceosome and is involved 
in maintaining the activate site conformation and in 
promoting splicing reactions [11, 58]. UBL5 may play 
a role in both early and later stages of splicing through 
binding to the DEAD-box helicase PRPF5/DDX46 which 
is involved in spliceosome assembly and to SART1/Snu66 
a component of the U4/U6.U5 tri-snRNP [59, 60]. USP39 
contributes to the recruitment of the U4/U6.U5 complex to 
splice sites [61]. PRPF19 is part of the nineteen complex 
(NTC) which participates in activation of the spliceosome 
[62, 63]. We compared the effect of knockdown of these 
splicing factors on viability (live cell number) and death 
in normal human fibroblasts (NHF) and normal human 
keratinocytes (NHK) and cell lines derived from primary 
and metastatic cSCCs from RDEB patients (SCCRDEB4 
and SCCRDEBMet) and a metastatic cSCC from a 
transplant patient (SCCTMet). The effect of knockdown 
of the SF3B subunit SF3B1 was also investigated because 
it is a target of spliceosome inhibitors [29–31]. The use 
of a positive control cytotoxic siRNA and analysis of 
splicing factor knockdown indicated high transfection 
efficiency in normal and tumour cells (Figure 1 and 
Supplementary Figure 1). Splicing factor knockdown 
caused a greater reduction in the viability of cSCC 
cell lines than normal skin cells (Figure 1, left panels). 
Strikingly, splicing factor depletion also generally caused 
a higher level of death in the cSCC cells (Figure 1 right 
panels). Knockdown of SF3B1, PRPF8, UBL5 and USP39 
increased cell death in all cSCC cell lines. Suppression of 
the SF3B complex subunits PHF5A, SF3B1 and SF3B3 
resulted in a similar high level of death in SCCRDEB4 
cells. In contrast, depletion of SF3B1 was more effective 
in killing SCCRDEBMet and SCCTMet cells than 
knockdown of PHF5A or SF3B3. Suppression of PRPF19 
killed SCCRDEB4 and SCCTMet cell lines but it did not 
increase cell death in SCCRDEBMet cells. These results 
indicate that splicing factor depletion can selectively kill 
cSCC cells derived from both primary and metastatic 
tumours but there are variations in the potency of the anti-
cSCC activity of targeting different splicing factors. 
The effect of the small molecule SF3B1 inhibitor 
pladienolide B on cell viability and death was determined 
in normal skin cells and twelve cSCC cell lines. cSCC 
cell viability was generally more pladienolide B-sensitive 
than that of NHK and normal keratinocytes from an RDEB 
patient (RDEBK) (Figure 2, left panels). The viability 
of NHF was partially reduced at low pladienolide B 
concentrations due to inhibition of proliferation and further 
inhibited at high concentrations associated with increased 
cell death (Figure 2B). Importantly, most cSCC cell lines 
were killed at lower concentrations of pladienolide B than 
required to kill normal skin cells, including all cSCC lines 
derived from RDEB and transplant patients (Figure 2, 
right panels). SCCIC1Met, SCCIC8 and SCCIC18 cells 
were the least sensitive to pladienolide B-induced death. 
In some instances the proportion of dead cells declined 
at higher pladienolide B concentrations. This may reflect 
a shift in the balance of pro and anti-death pathways due 
to variations in the degree of inhibition of splicing events 
at different pladienolide B concentrations. Overall these 
results indicate that small-molecule inhibition of SF3B1 
has potential for cSCC therapy. 
c-MYC is a determinant of cSCC sensitivity to 
targeting the spliceosome 
Ectopic expression of c-MYC in normal cells 
enhances sensitivity to spliceosome inhibition [19, 38]. 
Alterations in mRNA splicing of BCL-2 family members 
can promote cell death brought about by targeting the 
spliceosome [43–48]. We investigated the involvement 
of c-MYC and regulation of BCL-2 family members 
in spliceosome-suppression induced death in cSCC 
cells. SF3B1 was selected for further study because of 
its importance as a small-molecule target [20, 29, 31]. 
PRPF8 was also selected to investigate whether common 
mechanisms may be involved in determining sensitivity to 
different ways of targeting the spliceosome. Knockdown 
of c-MYC attenuated cell death caused by depletion of 
PRPF8 or SF3B1 in SCCRDEBMet cells and depletion 
of PRPF8 in SCCRDEB4 cells (Figure 3). In contrast, 
knockdown of c-MYC had no effect on cell death 
resulting from depletion of SF3B1 in the SCCRDEB4 cell 
line (Figure 3B). SCCRDEBMet and SCCRDEB4 cells 
express MCL-1 and BCL-X but relatively low levels of 
BCL-2 (Supplementary Figure 2). There was little or no 
effect of PRPF8 or SF3B1 knockdown on the level of 
MCL-1 or BCL-X under circumstances where cell death 
was dependent on c-MYC. However, in SCCRDEB4 
cells where SF3B1 knockdown-induced cell death 
was c-MYC-independent, full-length MCL-1 protein 
expression was reduced by SF3B1 depletion (Figure 3B). 
Similarly, c-MYC knockdown reduced the sensitivity of 
SCCRDEBMet and SCCRDEB4 lines to death induced 
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Figure 1: Splicing factor knockdown can selectively kill cSCC cells. Normal skin cells (NHF, NHK) and cSCC lines derived 
from a primary tumour (SCCRDEB4) and a metastatic tumour (SCCRDEBMet) from RDEB patients and a metastatic tumour from a 
transplant recipient (SCCTMet) were mock transfected (−), transfected with a non-targeting siRNA (Control) or transfected with three 
individual siRNAs targeting the indicated splicing factors. A cytotoxic siRNA (TOX) was used as a positive control for transfection 
efficiency. Cell viability (live cell number) expressed as a percentage of carrier alone and the percentage of dead cells were assayed by real-
time imaging 96 hours after transfection. The values are the mean −/+ range of two independent experiments. Splicing factor knockdown 
generally caused a larger reduction in viability and a greater level of cell death in cSCC cell lines than in normal skin cells. 
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by the SF3B1 inhibitor pladienolide B (Figure 4A). Full-
length MCL-1 and BCL-X protein levels were not altered 
at concentrations of pladienolide B that selectively kill 
cSCC cells (Figure 4B). However, full-length MCL-1 
protein expression was reduced and the expression of 
low molecular weight MCL-1 isoforms was increased at 
relatively high concentrations of pladienolide B at which 
cell death was unaffected by c-MYC knockdown. In cSCC 
cells endogenous c-MYC can thus confer sensitivity to 
interference with the spliceosome. Strong suppression 
of SF3B1 can however kill cSCC cells independently of 
c-MYC. Altered MCL-1 expression provides a marker 
of strong suppression of SF3B1 and could contribute to 
c-MYC-independent cell death. However, changes in 
MCL-1 expression are not involved in killing cSCC cells 
at low tumour-selective concentrations of pladienolide B. 
Consistent with previous results c-MYC protein 
levels were upregulated compared to normal skin cells 
in fifteen of the eighteen cSCC cell lines analysed 
which provides a mechanism for the cSCC selectivity of 
interference with the spliceosome (Figure 5A) [19, 38, 64, 
65]. Consistent with this, two of the three cSCC cell lines 
(SCCIC1Met and SCCIC18) with low c-MYC expression 
were relatively insensitive to pladienolide B (Figures 2 
and 5B). We also observed that PRPF8 and SF3B1 were 
generally upregulated in cSCC cells (Supplementary 
Figure 2). This may be due to an increased demand 
for splicing in the tumour cells, however there was no 
association between levels of these splicing factors and the 
differential pladienolide B sensitivity of cSCC cell lines. 
The effect of c-MYC knockdown on changes in 
splicing caused by suppression of SF3B1 and PRPF8 
was investigated. Selected splicing events known to 
be dependent on PRPF8 and/or SF3B1 were assessed 
(Figure 5C) [49, 66, 67]. SF3B1 depletion resulted in 
exon skipping in MDM2 and RBM5 mRNAs and intron 
retention in separase mRNA. PRPF8 depletion caused 
an increase in separase mRNA intron retention. c-MYC 
knockdown reduced the severity of these alterations in 
splicing. The effect of pladienolide B on the splicing 
Figure 2: The small-molecule SF3B1 inhibitor pladienolide B selectively kills cSCC cell lines. Normal skin cells and cSCC 
cell lines were incubated with the indicated concentration of pladienolide B (PD) for 72 hours. Cell viability (live cell number) expressed 
as a percentage of carrier alone and the percentage of dead cells were assayed by real-time imaging. Values are the mean −/+ SEM of at 
least three independent experiments (NHF, RDEBK, SCCRDEB4, SCCRDEBMet, SCCIC8, SCCIC12, SCCIC18) or the mean −/+ range 
of two independent experiments (NHK, SCCRDEB2, SCCRDEB3, SCCT, SCCTMet, SCCT8, SCCIC1, SCCIC1Met). (A) Keratinocytes 
(RDEBK) and cSCC cell lines derived from RDEB patients (SCCRDEB). (B) NHF and NHK. cSCC cell lines derived from transplant 
patients (SCCT). (C) cSCC cell lines derived from immunocompetent patients (SCCIC) The majority of cSCC cell lines were killed at 
lower concentrations of pladienolide B than normal skin cells. 
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Figure 3: Endogenous c-MYC can confer sensitivity to PRPF8 and SF3B1 knockdown in cSCC cells. Cells were mock 
transfected (−) or transfected with the indicated combinations of non-targeting siRNA (Control) and two individual siRNAs: (A) and (B) 
targeting c-Myc, PRPF8 and SF3B1. The percentage of dead cells was determined by real-time imaging. The values are the mean −/+ 
SD of three independent experiments. Expression of the indicated proteins was analysed by western blotting. (A) SCCRDEBMet cells. 
(B) SCCRDEB4 cells. c-MYC depletion attenuated cell death resulting from splicing factor knockdown in all cases except for SF3B1 
knockdown in SCCRDEB4 cells. Splicing factor knockdown had little effect on full-length MCL-1 or BCL-X protein expression with the 
exception of SF3B1 knockdown in SCCRDEB4 cells which reduced MCL-1 levels. 
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events examined was similar to that of SF3B1 knockdown. 
Depletion of c-MYC attenuated the changes in the splicing 
of RBM5 and separase mRNAs caused by pladienolide 
B (Figure 5D). Alternatively/aberrantly spliced forms 
of mRNA can be degraded by the translation coupled 
nonsense-mediated mRNA decay (NMD) pathway [68, 
69]. Similar results were observed in the absence and 
presence of the translation inhibitor cycloheximide 
which was added to block degradation of potential NMD 
substrates. These data indicate that endogenous c-MYC 
can promote alterations in splicing caused by targeting the 
spliceosome. 
Wild-type p53 participates in killing normal skin 
cells following suppression of SF3B1
We previously observed that the p53 pathway is 
involved in sensing alterations in the spliceosome [49]. 
The role of p53 in the response of normal skin cells to 
pladienolide B was investigated to determine if p53 
activation may limit the therapeutic window for SF3B1 
inhibition. Knockdown of p53 reduced pladienolide 
B-dependent death in both NHF and RDEBK cells (Figure 
6A and 6B). In normal skin cells protein expression of the 
p53 repressor MDMX was reduced at low concentrations 
of pladienolide B, associated with changes in the ratio of 
alternatively spliced forms of MDMX mRNA (Figure 
6C and 6D). This was not sufficient to cause marked p53 
accumulation or cell death. The pladienolide B concentration 
dependency for killing normal skin cells corresponded to 
that for causing: altered MDM2 mRNA splicing, a reduction 
in full-length MDM2 protein expression and a robust 
increase in p53 protein levels (Figures 2 and 6). These 
results indicate that induction of wild-type p53 due to loss 
of full-length MDM2, in the context of reduced MDMX 
expression, plays an important role in killing normal skin 
cells in response to pladienolide B. 
Normal p53 function is lost, most commonly 
by its missense mutation, in all cSCC cell lines [64]. 
We confirmed that knockdown of mutant p53 in cSCC 
cells did not attenuate pladienolide B-induced death 
(Supplementary Figure 3). Pladienolide B and SF3B1 
knockdown reduced MDMX and MDM2 protein 
expression in cSCC lines, indicating that these effects can 
occur independently of wild-type p53 (Supplementary 
Figures 4 and 5). Low molecular weight protein isoforms 
Figure 4: In cSCC cells endogenous c-MYC confers sensitivity to the SF3B1 inhibitor pladienolide B. (A) SCCRDEBMet 
and SCCRDEB4 cells were mock transfected (-) or transfected with the indicated siRNAs 24 hours prior to incubation with pladienolide B 
(PD). The percentage of dead cells was determined by real-time imaging. Values are the mean −/+ SEM of three independent experiments. 
Knockdown of c-MYC increased resistance to pladienolide B-induced death. (B) SCCRDEBMet and SCCRDEB4 cells were treated 
with pladienolide B (PD) and protein expression was analysed by western blotting. Full-length MCL-1 expression was reduced only at a 
relatively high pladienolide B concentration which was more than 10-fold greater than required to kill cSCC cells and at which cell death 
was not affected by c-MYC depletion. 
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of MDM2 were detected in cells with wild-type p53 
following treatment with pladienolide B but not in cSCC 
cells with mutant p53 (Figure 6 and Supplementary 
Figure 4). Consistent with this, pladienolide B-dependent 
expression of short MDM2 protein isoforms was 
attenuated by knockdown of wild-type p53 in NHF and 
loss of full-length wild-type p53 in HCT116 cells (Figure 
6B and Supplementary Figure 6B). The mechanism 
underlying the p53-dependent accumulation of MDM2 
isoforms remains unclear but it could involve elevated 
Figure 5: c-MYC is upregulated in cSCC cell lines and promotes altered splicing following interference with the 
spliceosome. (A) c-MYC protein expression in normal skin cells (NHF, NHK and RDEBK) and a panel of cSCC cell lines was analysed 
72 hours after plating. NHF1 and 2 and NHK1 and 2 were from different donors. c-MYC protein expression was higher in cSCC cells 
compared to normal cells with the exception of SCCIC1Met, SCCIC12 and SCCIC18 cell lines. (B) Cell death at 10 nM pladienolide B 
(taken from Figure 2). Normal cells and two of the three cSCC cell lines with low c-MYC expression were relatively resistant to pladienolide 
B. (C) SCCRDEBMet cells were transfected with the indicated combinations of siRNAs. RNA was extracted 48 hours after transfection. 
One set of cells were treated with cycloheximide (20 μg/ml) 6 hours before harvesting to inhibit NMD (right panel). PCR was carried out 
using primers complementary to the indicated exons (E). (D) SCCRDEBMet cells were transfected with non-targeting siRNA (Control) 
or siRNA c-MYC (B) 24 hours before the addition of 10 nM pladienolide B (PD). One set of cells was treated with cycloheximide 6 hours 
before the end of the incubation (right panel). Samples were harvested for RNA extraction 24 hours after the initiation of pladienolide B 
treatment. c-MYC knockdown partially reversed alterations in mRNA splicing caused by interference with the spliceosome. 
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MDM2 gene transcription due to upregulation of wild-type 
p53 [49]. SF3B1 suppression did not increase levels of 
mutant p53 in cSCC cell lines (Supplementary Figures 4A 
and 5A). This is consistent with the high protein stability of 
mutant p53 in tumours [70]. On the contrary, we observed 
that 3 to 30 nM pladienolide B and SF3B1 knockdown 
actually decreased mutant p53 protein expression to some 
extent in cSCC cells. This is unlikely to make a major 
contribution to death caused by SF3B1 suppression 
through attenuation of mutant p53 gain of function activity 
because p53 could be robustly knocked down in cSCC cell 
lines without causing marked cell death (Supplementary 
Figure 3). 
We have previously observed in tumour cells that 
MDMX protein levels are reduced by suppression of a 
range of splicing factors but that MDM2 mRNA splicing 
is selectively sensitive to knockdown of SF3B1 [49]. 
Consistent with this, PRPF8 knockdown in cSCC cells 
reduced full-length MDMX protein expression but it 
did not diminish MDM2 protein levels (Supplementary 
Figure 5B). Targeting a range of splicing factors, including 
SF3B1, with previously validated siRNAs reduced MDMX 
protein levels in NHF (Figure 7A) [49]. In most cases 
this was associated with an altered ratio of alternatively 
spliced forms of MDMX mRNA (Figure 7B). In contrast, 
knockdown of SF3B1 but not the other splicing factors 
disrupted MDM2 mRNA splicing (Figure 7B). Depletion 
of at least some of these splicing factors can kill cSCC cells 
(Figure 1). This indicates that targeting splicing factors 
other than SF3B1 could have anti-cSCC activity without 
altering MDM2 mRNA splicing in normal cells. This 
would be advantageous because loss of MDMX alone has 
less impact on normal tissues than loss of both MDMX and 
MDM2 [51, 71–73]. SF3B1 knockdown altered MDM2 
splicing in NHF but this did not change MDM2 protein 
expression and p53 levels were not strongly upregulated by 
SF3B1 knockdown (Figure 7A). This presumably reflects 
partial depletion of SF3B1 and is consistent with the 
relatively low level of death induced by SF3B1 knockdown 
in NHF and a requirement for stronger suppression of the 
spliceosome to have effects on splicing in normal skin 
cells. At high concentrations pladienolide B was able to 
suppress SF3B1 sufficiently to reduce full-length MDM2 
protein expression in normal cells (Figure 6). 
To begin to investigate the involvement of 
endogenous wild-type p53 in killing tumour cells in 
response to SF3B1 inhibition the effects of pladienolide 
B were compared in HCT116 (p53+/+) colon cancer cells 
and a derivative cell line lacking full-length p53 (p53-
/−). The absence of full-length p53 markedly reduced 
cell death caused by pladienolide B (Supplementary 
Figure 6A). HCT116 (p53+/+) cells were killed at lower 
concentrations of pladienolide B than normal cells 
(Supplementary Figure 6A and Figures 2 and 6A). A 
reduction in MDM2 and MDMX protein expression and 
accumulation of p53 also occurred at lower concentrations 
of pladienolide B in HCT116 cells than in normal cells 
(Supplementary Figure 6B and Figure 6C). These results 
indicate that wild-type p53 upregulation associated with 
downregulation of MDM2 and MDMX can also play a 
dominant role in the killing of tumour cells by SF3B1 
inhibition and that there may be a level of tumour 
selectivity because of the greater sensitivity of MDM2/
MDMX expression in transformed cells. 
DISCUSSION
This study indicates that targeting the spliceosome 
has potential for the treatment of cSCC. We show that 
endogenous c-MYC participates in sensitising cSCC 
cells to interference with the spliceosome. We provide 
evidence for a role of the p53 pathway in determining the 
therapeutic window for SF3B1 suppression. 
Small molecule inhibition of SF3B1 can selectively 
kill cSCC cells. There is an ongoing clinical trial for 
haematological malignancies involving systemic delivery 
of an SF3B1 inhibitor and additional SF3B inhibitors are 
candidates for testing in the clinic [28]. cSCC cell lines 
can also be more sensitive than normal skin cells to death 
induced by suppression of splicing factors other than 
SF3B1. This suggests that SF3B1-independent targeting 
of the spliceosome could also be effective for treating 
cSCCs. There are variations between cSCC cell lines in 
the potency of targeting different splicing factors. This 
may be due to depletion of different components of the 
spliceosome influencing distinct subsets of splicing events 
[22]. Divergent downstream mechanisms could mediate 
the anti-tumour activity of different ways of targeting the 
spliceosome. There are a number of mechanisms through 
which interference with the spliceosome and altered pre-
mRNA splicing could cause cell death including: reduced 
expression of components or regulators of key cellular 
pathways, the inappropriate expression of protein isoforms 
that interfere with specific cellular pathways and the 
generation of aberrant misfolded proteins which trigger 
protective mechanisms such as the unfolded protein 
response [74]. It would be of interest to identify the 
downstream mechanisms involved in killing cSCC cells 
following the suppression of different components of the 
spliceosome. This would aid in determining how to target 
the spliceosome for cSCC therapy and may lead to the 
discovery of additional makers of sensitivity and potential 
combinatorial therapeutic approaches. 
Our study indicates that c-MYC upregulation 
contributes to the cSCC selectivity of interference with the 
spliceosome. This could be due at least in part to its ability 
to increase the severity of alterations in splicing caused 
by targeting the spliceosome. An implication of this is 
that irrespectively of whether different ways of targeting 
the spliceosome have anti-tumour activity through 
divergent downstream mechanisms c-MYC could act as a 
common sensitizer by increasing the extent of alterations 
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in splicing. These results are consistent with a model in 
which high levels of c-MYC stresses the spliceosome by 
increasing the demand for splicing through widespread 
upregulation of transcription [19]. Elevated c-MYC can 
cause an increase in total cellular pre-mRNA/mRNA 
levels through direct transcriptional activation of genes 
and/or by more indirect mechanisms [19, 75–77]. c-MYC 
protein expression is high in around 80% of patient cSCCs 
Figure 6: p53 plays a major role in killing normal skin cells following exposure to pladienolide B. (A) 24 hours prior to 
the addition of pladienolide B (PD) NHF and RDEBK were transfected with three individual siRNAs targeting all known isoforms of p53. 
Cell death was analysed by real-time imaging 72 hours after pladienolide B addition. Knockdown of p53 reduced sensitivity to pladienolide 
B. (B) NHF were transfected with three individual p53 siRNAs. 24 hours after transfection cells were treated with carrier (-) or 100 nM 
pladienolide B (+). Cells were harvested at the time of drug addition (T0) and 24 hours later. p53 was efficiently knocked down by all of 
the siRNAs. (C) NHF, RDEBK and NHK were treated with pladienolide B (PD) for 24 hours. Protein expression was analysed by western 
blotting. Strong p53 upregulation was associated with reduced full-length MDM2 (MDM2FL) protein expression. (D) NHF and NHK cells 
were treated with pladienolide B (PD) for 24 hours. PCR was carried out with primers complementary to the indicated exons (E). 10 and 
100 nM pladienolide B altered the ratio of alternatively spliced forms of MDMX mRNA and 100 nM pladienolide B dramatically interfered 
with MDM2 mRNA splicing. 
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[39, 40, 78]. This could provide a marker for sensitivity to 
spliceosome inhibition, although unsurprisingly our data 
indicate that other markers would also be required. This 
might include markers of c-MYC transcriptional activity 
or of additional mechanisms of sensitivity/resistance. 
The p53 pathway is responsive to interference with 
the spliceosome. This could reflect a normal role in sensing 
and protecting against potentially tumour promoting 
alterations in the spliceosome. There are often widespread/
global changes in splicing during tumour development 
which can be linked with aberrant expression of splicing 
factors and to splicing factor mutations [79–84]. SF3B1 
is the most frequently mutated splicing factor in tumours. 
The spliceosome is also involved in preventing DNA 
damage, ensuring proper mitosis and maintaining genome 
stability [85–87]. We observed that knockdown of all 
splicing factors tested reduces MDMX protein expression 
in normal skin cells, including splicing factors outwith the 
SF3B complex that are associated with different snRNPs 
and splicing factors involved in the formation of multi-
snRNP complexes. This is consistent with our previous 
observations and is further evidence that MDMX may 
act as a relatively general sensor of perturbations in the 
spliceosome [49]. Of the splicing factors that we have 
targeted to date only SF3B1 knockdown results in an 
alteration in MDM2 splicing. The convergence on SF3B1 
is intriguing, in that: MDM2 splicing appears to be 
particularly sensitive to SF3B1 suppression, SF3B1 is the 
target for multiple families of naturally occurring splicing 
modulators and there is an elevated SF3B1 mutation rate 
in cancer. This is despite the multitude of splicing factors 
with important roles in splicing. 
Death of normal skin cells at high concentrations 
of pladienolide B is p53-dependent and is associated with 
altered mRNA splicing and reduced protein expression 
of both MDMX and MDM2. MDMX is reduced at lower 
pladienolide B concentrations than MDM2. However, this 
reduction in MDMX is not sufficient to cause strong p53 
accumulation or cell death. This is consistent with the 
severity of p53-dependent effects on normal tissues in 
mouse knockout models in which loss of MDM2 is more 
deleterious than loss of MDMX and targeting MDMX and 
MDM2 simultaneously has the greatest impact [51, 71–73]. 
It is also consistent with observations that the effects of 
MDMX suppression on p53 protein levels are generally 
smaller than those of targeting MDM2 [51, 52]. 
p53 function is commonly lost through mutation in 
cSCC [64, 88–90]. We confirmed that missense mutant 
p53 depletion did not attenuate pladienolide B-induced 
cell death in cSCC cells. Knockdown of splicing factors 
outwith the SF3B complex can kill cSCC cells expressing 
mutant p53 without altering MDM2 splicing. This raises 
the possibility that by not depleting both MDM2 and 
MDMX and thus avoiding strong p53 upregulation in 
normal cells small-molecules that target the spliceosome 
through SF3B1-independent mechanisms could have even 
greater selectivity than SF3B1 inhibitors for cSCCs with 
mutant p53. Furthermore, it may be advantageous to treat 
cSCCs where p53 is mutated with an SF3B1-independent 
inhibitor because a reduction in MDMX and MDM2 levels 
could enhance the gain of function activity of mutant 
p53. Although not the case in the cSCC lines examined, 
MDM2 depletion in some contexts can increase mutant 
p53 expression [91]. In addition, MDM2 and MDMX have 
been reported to suppress at least some gain of function 
activities of mutant p53 [92, 93]. 
As p53 is mutated in all existing cSCC lines we 
used HCT116 colon cancer cells to explore the role of 
Figure 7: Altered MDM2 mRNA splicing is selectively caused by suppression of SF3B1. NHF were transfected with siRNAs 
targeting the indicated splicing factors. Samples were analysed 48 hours after transfection. (A) Western blot analysis. Splicing factor 
knockdown reduced MDMX protein expression. (B) PCR analysis. With the exception of U1-70K, suppression of splicing factors altered 
the ratio of alternatively spliced forms of MDMX. Only SF3B1 knockdown altered splicing of MDM2 mRNA. 
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wild-type p53 in the response of tumours cells to SF3B1 
inhibition. These cells undergo p53-dependent cell 
death at lower pladienolide B concentrations than the 
normal cells examined. This indicates that wild-type p53 
can contribute to the selective killing of tumour cells. 
Intriguingly, full-length MDMX and MDM2 protein 
expression was reduced at lower concentrations of 
pladienolide B in HCT116 cells than in the normal cells. 
A number of agents have been developed for treating 
cancers with wild-type p53 that target MDMX and 
MDM2 alone or in combination [94–96]. The majority 
of these prevent the interaction of MDMX and/or MDM2 
with p53. However, there are also agents with different 
mechanisms of action including inhibitors of MDMX/
MDM2 heterodimerisation and antisense oligonucleotides 
that promote MDMX exon skipping. Although not 
specific for the p53 pathway, modulation of SF3B1 
is another way of suppressing MDMX and MDM2. 
Targeting the spliceosome by SF3B1-independent 
mechanisms also provides a potential therapeutic 
approach for reducing MDMX expression. This study 
indicates that there may be a window for tumour-selective 
depletion of MDMX/MDM2 by spliceosome inhibition. 
Additional work is required to identify the optimum ways 
of targeting the spliceosome to activate wild-type p53 in 
tumour cells with the least potential for adverse effects in 
normal tissue. 
It would be of interest in further studies to 
compare the anti-tumour activity and selectivity of 
SF3B1-independent small molecule suppressors of the 
spliceosome and to investigate the roles of c-MYC, 
the p53 pathway and their cross-talk in determining 
responses. Inhibitors which directly target components of 
the spliceosome other than SF3B1 are being developed 
[97–100]. There are also inhibitors of kinases that play 
important roles in regulating the spliceosome [101]. 
In addition, the therapeutic potential of targeting the 
spliceosome could be further mapped by the systematic 
knockdown of all core splicing factors and key 
spliceosome regulators in normal cells and tumour cells 
with different p53 status and determination of the effect on 
cell viability/death, MDM2, MDMX and p53. This would 
contribute to the identification of the best approaches for 
targeting the spliceosome for cancer therapy. 
MATERIALS AND METHODS
Cell culture
Cells were cultured at 37°C and 5% CO2 in a 
humidified atmosphere. Normal keratinocytes (NHK and 
RDEBK) and cSCC cells were isolated and maintained 
as described [64, 102]. These cells were cultured in 
keratinocyte medium containing 10% FBS and growth 
factors [102]. Normal keratinocytes were cultured in the 
presence of a mitotically inactivated 3T3 fibroblast feeder 
layer. RDEBK were routinely expanded using the ROCK 
inhibitor Y-27632 (1254: Tocris Bioscience, Bristol, 
UK) and this was removed 48 hours before the start of 
experiments [103]. SCCT (MET1) and SCCTMet (MET4) 
cell lines were described previously [104]. SCCRDEB4 
and SCCRDEBMet (SCCRDEB70) cell lines were from 
different patients. SCCRDEBMet and RDEBK cells 
were a gift from Dr Andrew P. South (Thomas Jefferson 
University). The tissue from which these cells were 
derived was provided by Jemima E. Mellerio (King’s 
College London) and Julio C. Salas-Alanís (DEBRA 
Mexico) [65]. SCCT/SCCTMet and SCCIC1/SCCIC1Met 
cell lines are from paired primary and metastatic tumours. 
NHF were isolated as described and routinely cultured in 
Dulbecco’s Modified Eagle Medium (419660-29: Gibco, 
Thermo Fisher Scientific, Waltham, MA USA) containing 
10% FBS [105]. For experiments, normal skin cells 
and cSCC lines were plated in the absence of feeders in 
keratinocyte medium containing 10% serum and growth 
factors with no added EGF. HCT116 cells were cultured 
and plated in McCoy’s 5A medium (26600-023: Gibco, 
Thermo Fisher Scientific), supplemented with 10% FBS. 
Pladienolide B treatment
Pladienolide B (sc-391691: Santa Cruz 
Biotechnology, Heidelberg, Germany) was dissolved 
in DMSO (5 mM stock) and was added to cells 16 to 
24 hours after plating/transfection with siRNAs unless 
otherwise indicated. 
siRNA transfection 
Dharmacon ON-TARGETplus modified siRNAs 
(Thermo Fisher Scientific) were used (Supplementary 
Figure 7A) with the exception of siRNA p53 (C) which 
is described previously [106]. Reverse transfection with 
synthetic siRNA duplexes (10 nM final concentration) was 
carried out using Invitrogen Lipofectamine RNAiMAX 
transfection reagent (13778150: Thermo Fisher Scientific) 
according to the manufacturer’s instructions. 
Cell viability assays 
Cells were seeded into 96 well plates and cell 
viability (live cell number) and cell death were analysed 
according to the manufacturers’ instructions using an 
Incucyte ZOOM real-time imager (Essen BioScience 
Ltd, Welwyn Garden City, UK) and the CellTox Green 
cytotoxicity assay (G8731: Promega, Southampton, 
UK). Live cell number and cell death were generally 
analysed 96 hours after transfection with siRNAs and/
or 72 hours after pladienolide B addition. This was 
extended to 120 and 96 hours respectively for experiments 
investigating the effect of c-MYC and p53 knockdown in 
SCCRDEBMet cells. 
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Western blotting
Cell extracts were made by lysis into SDS 
electrophoresis sample buffer: 100 mM Tris pH 6.8, 4% 
SDS, 20% glycerol, 20 mM EDTA, 0.014% bromophenol 
blue. Western blotting was performed as described 
previously [107]. The primary antibodies used are listed 
in Supplementary Figure 7B. 
RNA preparation and PCR
Where indicated cells were treated with 
cycloheximide (20 μg/ml) for 6 hours before harvesting 
to block degradation of potential NMD substrates. Total 
RNA was extracted using RNeasy columns (Qiagen, 
Crawley, UK). 1 μg of RNA was reverse-transcribed 
using random primers (58875: Invitrogen, Thermo Fisher 
Scientific). The cDNA (5% of the reverse-transcription 
reaction) was amplified by PCR using the primers listed 
in Supplementary Figure 7C. After 40 cycles of 1 min at 
95°C, 45 s at 56°C and 1 min at 72°C, the products were 
analysed on agarose gels. 
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